All articles by Staff Writer
Staff Writer
MEDICA and COMPAMED: Medical technology business is profiting from strong appeal to international visitors
High proportion of decision-makers, unique variety of innovations and a high-calibre accompanying programme
COMPAMED 2023, between the poles of top innovation and regulation
The med-tech supply sector shows off its “high-performance mode”
Thermo Fisher Scientific to Acquire CorEvitas
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced it has entered into a definitive agreement to acquire CorEvitas, LLC (“CorEvitas”), a leading provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity (“Audax”), for $912.5 million in cash.
Annual Congress 2023 of the European Academy of Allergy and Clinical Immunology: Study Shows Promising Results for Immunotherapy Targeting Skin Cancer
A ground-breaking study was presented 10 June at the Hybrid Congress in Hamburg organized by the European Academy of Allergy & Clinical Immunology (EAACI). Study was conducted by researchers from King’s College London and Guy’s and St Thomas’ NHS Foundation Trust has revealed promising results for a new class of immunotherapy in the fight against aggressive skin cancer. The study investigates the efficacy of a novel antibody in targeting and treating melanomas, demonstrating its ability to activate the immune response and impede melanoma growth in mice.
Africa Health ExCon-2023: The Egyptian Authority for Unified Procurement (UPA) and the Arab Hospital Federation (AHF) signed a protocol on cooperation to consolidate the role of the Africa Health ExCon
The Egyptian Authority for Unified Procurement (UPA) and Arab Hospital Federation (AHF) on Tuesday signed a Protocol of Cooperation to enhance the role of the Africa Health ExCon-2023 in its second edition under the title ”Your gateway to Health and Innovation in Africa”. The Africa Health ExCon Exhibition is held under the patronage of His Excellency the Egyptian President Abdel Fattah El-Sisi. In addition, it will take place between the 7th and the 10th of June 2023 at the Egypt International Exhibition center in Cairo, Egypt.
Toronto Airport Authority Partners with Kraken Sense, a Leading Canadian Tech Company, as Part of Study to Combat COVID-19
TORONTO–(BUSINESS WIRE)–The Greater Toronto Airports Authority (GTAA) is partnering with Kraken Sense, a leader in real-time pathogen detection devices, as part of a study funded in part by the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to conduct tests on airport wastewater for Monkeypox and Omicron, a variant of SARS-CoV-2, the virus that causes COVID-19. Kraken Sense is testing multiple samples of wastewater at Toronto Pearson Airport using their technology to obtain quantitative results in under an hour without sacrificing the accuracy of results in contrast to traditional PCR technology, which can take multiple days to turnaround.
Ellipses Pharma Announces FDA Approval of IND Application for EP0042 for Patients With Acute Myeloid Leukaemia
LONDON–(BUSINESS WIRE)–Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for EP0042, a dual FLT-3 and Aurora kinase inhibitor.
AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference
MENLO PARK, Calif.–(BUSINESS WIRE)–AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the SVB Securities Global Biopharma Conference.
Thermo Fisher Scientific Partners with AstraZeneca to Develop Solid Tissue and Blood-Based Companion Diagnostic Test for Tagrisso
CARLSBAD, Calif.–(BUSINESS WIRE)– As part of a global, multiyear agreement, Thermo Fisher Scientific today announced it is working with AstraZeneca to develop a solid tissue and blood-based companion diagnostic (CDx) test for Tagrisso (osimertinib). The CDx will help identify patients with non-small cell lung cancer (NSCLC) who may be eligible for treatment with Tagrisso by identifying tumors that exhibit epidermal growth factor receptor (EGFR) alterations including exon 21 L858R mutations, exon 19 deletions or T790M mutations.
Lydus Medical Announces FDA Clearance of Vesseal™, The Microvascular Anastomosis Aid Device for Small Arteries
RA’ANANA, Israel, Jan. 10, 2023 /PRNewswire/ — Lydus Medical is pleased to announce that the Vesseal™ has received FDA clearance 510(k). The Vesseal™ is a microvascular anastomosis suture deployment system, for standardized omni-vessel anastomoses, enabling simple, fast, safe, and effective procedures.